Nationwide Fund Advisors’s Cardiff Oncology CRDF Stock Holding History

Nationwide Fund Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-205	Closed	-$17K	–	3209
2017 Q1	$17K	Sell	205 -67	-25%	-$9.1K	﹤0.01%	3100
2016 Q4	$41K	Hold	272	–	–	﹤0.01%	3031
2016 Q3	$88K	Hold	272	–	–	﹤0.01%	2930
2016 Q2	$89K	Hold	272	–	–	﹤0.01%	2951
2016 Q1	$91K	Hold	272	–	–	﹤0.01%	2860
2015 Q4	$106K	Buy	272 +16	+6%	+$6.27K	﹤0.01%	2820
2015 Q3	$105K	Buy	256 +37	+17%	+$19.4K	﹤0.01%	2879
2015 Q2	$160K	Buy	+219	New	+$155K	﹤0.01%	2822

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Nationwide Fund Advisors's CRDF Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Cardiff Oncology (CRDF) in Q2 2017, closing a stake of 205 shares — an estimated $17K sold.

Nationwide Fund Advisors first reported a position in CRDF in Q2 2015 and held it in 8 quarters. The position peaked at $160K in Q2 2015. 48 funds tracked by Wall St. Rank hold CRDF as of Q2 2017.

Nationwide Fund Advisors reported no remaining Cardiff Oncology position as of Q2 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 205 Cardiff Oncology shares in Q2 2017, an estimated $17K.
Nationwide Fund Advisors first reported a position in Cardiff Oncology in Q2 2015 and held it in 8 quarters.
Nationwide Fund Advisors's Cardiff Oncology position peaked at $160K in Q2 2015.
48 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.